NCT05269459View on ClinicalTrials.gov

Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

April 30, 2029

Conditions
PTSD
Interventions
DRUG

Cannabidiol Administered as Nantheia ATL5

Participants will take 4 gel capsules twice daily containing 100mg of Nantheia ATL5.

DRUG

Placebo

Participants will take 4 matching gel capsules twice daily containing no active drug.

Trial Locations (1)

68198

RECRUITING

University of Nebraska Medical Center, Omaha

Sponsors

Collaborators (1)

Ananda Scientific Inc
All Listed Sponsors
collaborator

Ananda Scientific Inc

UNKNOWN

collaborator

University of Texas at Austin

OTHER

lead

University of Nebraska

OTHER

NCT05269459 - Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults | Biotech Hunter | Biotech Hunter